Morgan Stanley Bicycle Therapeutics PLC Transaction History
Morgan Stanley
- $1.27 Trillion
- Q2 2024
A detailed history of Morgan Stanley transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, Morgan Stanley holds 1,231,573 shares of BCYC stock, worth $28.6 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,231,573
Previous 1,516,715
18.8%
Holding current value
$28.6 Million
Previous $37.8 Million
34.0%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding BCYC
# of Institutions
111Shares Held
40.7MCall Options Held
3.4KPut Options Held
12.4K-
Baker Bros. Advisors LP New York, NY9.4MShares$218 Million2.53% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.49MShares$81 Million2.32% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.25MShares$52.3 Million0.69% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.12MShares$49.3 Million6.34% of portfolio
-
Armistice Capital, LLC New York, NY1.97MShares$45.8 Million0.52% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $689M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...